TAG:
esoteric lab test
Lab Test Utilization Delivers Big Gains at Cleveland Clinic
CEO SUMMARY: Since the launch of a laboratory test utilization program in 2011 at the Cleveland Clinic, more than 35,000 duplicate or inappropriate test orders have been stopped. The test utilization team introduced five initiatives that are not designed to cut spending but to in…
Lab Testing, Pathology Is Fast-Growing in China
CEO SUMMARY: It was record attendance at the major pathology congress which took place in Hangzhou, China, last month. Because of the ongoing growth of China’s economy, the demand for healthcare—and for high-quality clinical lab and pathology testing—is rising at an accelerated pace…
UnitedHealth’s Decision Reveals Lab Market Shift
CEO SUMMARY: News that UnitedHealth Group, Inc. added Esoterix, Inc. to its national laboratory services contract is a big story. UnitedHealth’s decision to expand the laboratory panel demonstrates that factors other than lowest price played an important role. The move to supplement its…
New Market Channel For Esoteric Testing
CEO SUMMARY: It’s a new marketing model for specialty esoteric tests that presents both clinical and financial challenges to hospital and health system laboratories. Niche labs offering esoteric tests are sending sales reps directly to physicians and bypassing pathologists and lab direc…
ARUP & Mayo Respond To New Market Cycle
CEO SUMMARY: Since the beginning of 2002, several important events changed the competitive status quo among the nation’s leading providers of hospital send-out testing. As part of its ongoing assessment of this market segment, THE DARK REPORT provides strategic management insights from …
Dynacare’s IPO is Funded, Specialty Labs’ IPO is Next
IT WAS A DISAPPOINTING TRIP to the public equity markets for Dynacare, Inc. last month. The lab company raised only $50 million in its initial public offering (IPO). Dynacare had hoped to harvest as much as $89 million from this IPO. Plans were to sell seven million shares at about …
CURRENT ISSUE
Volume XXXI, No. 5 – April 8, 2024
The fragmentation of consumer markets is reflected in clinical lab services, and The Dark Report examines this trend and how it will impact labs in the coming years. Also, The Dark Report notes that the FDA has issued a controversial memo to reclassify many high-risk IVD assays.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.